Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors

NCT00003518 is registered in ClinicalTrials.gov with Eastern Cooperative Oncology Group as lead sponsor.

NCT NCT00003518
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003518 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors
Lead sponsor
Eastern Cooperative Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
January 25, 1999
Completion date
Not reported
Enrollment
44 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, testicular germ cell tumor